Mapacalcine Protects Mouse Neurons against Hypoxia by Blocking Cell Calcium Overload

PLoS ONE

Volumn 8, Issue 7, 2013, Pages

  Moha ou Maati, Hamid ^a   Widmann, Catherine ^a   Gallois, Djamila Sedjelmaci Bernard ^a   Heurteaux, Catherine ^a   Borsotto, Marc ^a   Hugues, Michel ^b  

^a INSTITUT DE PHARMACOLOGIE MOLÉCULAIRE ET CELLULAIRE   (France)

^b CNRS   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AMPA RECEPTOR; CALCIUM CHANNEL L TYPE; GLUTAMIC ACID; MAPACALCINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NEUROPROTECTIVE AGENT; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; BRAIN CELL; CALCIUM CELL LEVEL; CELL MEMBRANE DEPOLARIZATION; CELL SURVIVAL; CLIONA VASTIFICA; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG BINDING; DRUG BINDING SITE; DRUG EFFICACY; DRUG MECHANISM; DRUG TARGETING; HYPOXIA; MARINE SPECIES; MOUSE; NERVE CELL NECROSIS; NEUROPROTECTION; NONHUMAN; PHARMACOLOGICAL BLOCKING; SPONGE (PORIFERA);

ANIMALS; CALCIUM; CALCIUM CHANNEL BLOCKERS; CALCIUM CHANNELS, L-TYPE; CELL HYPOXIA; CEREBRAL CORTEX; EMBRYO, MAMMALIAN; GLUCOSE; HEK293 CELLS; HUMANS; MALE; MEMBRANE POTENTIALS; MICE; NEURONS; OXYGEN; PATCH-CLAMP TECHNIQUES; PORIFERA; PRIMARY CELL CULTURE; PROTEINS; RECEPTORS, AMPA; RECEPTORS, N-METHYL-D-ASPARTATE;

CLIONA VASTIFICA;

EID: 84879759244     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0066194     Document Type: Article

References (44)

1. Go AS, Mozaffarian D, Roger VL, Benjamin EJ, Berry JD, et al. (2013) Heart disease and stroke statistics - 2013 update: a report from the American Heart Association. Circulation 127: e6-e245.
2. Dingledine R, Borges K, Bowie D, Traynelis SF, (1999) The glutamate receptor ion channels. Pharmacol Rev 51: 7-61.
3. McLennan H, (1983) Receptors for the excitatory amino acids in the mammalian central nervous system. Prog Neurobiol 20: 251-271.
4. Choi DW, (1988) Glutamate neurotoxicity and diseases of the nervous system. Neuron 1: 623-634.
5. Meldrum BS, (1995) Excitatory amino acid receptors and their role in epilepsy and cerebral ischemia. Ann N Y Acad Sci 757: 492-505.
6. Rothman SM, Olney JW, (1986) Glutamate and the pathophysiology of hypoxic - ischemic brain damage. Ann Neurol 19: 105-111.
7. Simon RP, Swan JH, Griffiths T, Meldrum BS, (1984) Blockade of N-methyl-D-aspartate receptors may protect against ischemic damage in the brain. Science 226: 850-852.
8. Brenman JE, Christopherson KS, Craven SE, McGee AW, Bredt DS, (1996) Cloning and characterization of postsynaptic density 93, a nitric oxide synthase interacting protein. J Neurosci 16: 7407-7415.
9. Kornau HC, Schenker LT, Kennedy MB, Seeburg PH, (1995) Domain interaction between NMDA receptor subunits and the postsynaptic density protein PSD-95. Science 269: 1737-1740.
10. Muller BM, Kistner U, Kindler S, Chung WJ, Kuhlendahl S, et al. (1996) SAP102, a novel postsynaptic protein that interacts with NMDA receptor complexes in vivo. Neuron 17: 255-265.
11. Azimi-Zonooz A, Kawa CB, Dowell CD, Olivera BM, (2001) Autoradiographic localization of N-type VGCCs in gerbil hippocampus and failure of omega-conotoxin mVIIA to attenuate neuronal injury after transient cerebral ischemia. Brain Res 907: 61-70.
12. Ginsberg MD, (2008) Neuroprotection for ischemic stroke: past, present and future. Neuropharmacology 55: 363-389.
13. Lukic-Panin V, Kamiya T, Zhang H, Hayashi T, Tsuchiya A, et al. (2007) Prevention of neuronal damage by calcium channel blockers with antioxidative effects after transient focal ischemia in rats. Brain Res 1176: 143-150.
14. Madden KP, Clark WM, Marcoux FW, Probert AW Jr, Weber ML, et al. (1990) Treatment with conotoxin, an 'N-type' calcium channel blocker, in neuronal hypoxic-ischemic injury. Brain Res 537: 256-262.
15. Wahlgren NG, Ahmed N, (2004) Neuroprotection in cerebral ischaemia: facts and fancies - the need for new approaches. Cerebrovasc Dis 17Suppl 1: 153-166.
16. Morel JL, Drobecq H, Sautiere P, Tartar A, Mironneau J, et al. (1997) Purification of a new dimeric protein from Cliona vastifica sponge, which specifically blocks a non-L-type calcium channel in mouse duodenal myocytes. Mol Pharmacol 51: 1042-1052.
17. Crenesse D, Neuilly G, Gugenheim J, Ferre C, Hugues M, (2003) Mapacalcine specifically blocks hypoxia-induced calcium influx in rat hepatocytes. Eur J Biochem 270: 1952-1957.
18. Mourre C, Lazou B, Cambar J, Neuilly G, Hugues M, (2003) Characterization of mapacalcine-sensitive Ca(2+) channels in rat kidney. Biochem Biophys Res Commun 308: 602-607.
19. Mourre C, Mokrzycki N, Neuilly G, Richeux F, Creppy EE, et al. (2000) Distribution of mapacalcine receptors in the central nervous system of rat using the [125I]-labeled mapacalcine derivative. Brain Res 858: 136-142.
20. Vidalenc P, Morel JL, Mironneau J, Hugues M, (1998) 125I-Labelled mapacalcine: a specific tool for a pharmacological approach to a receptor associated with a new calcium channel on mouse intestinal membranes. Biochem J 331 (Pt 1): 177-184.
21. Heurteaux C, Gandin C, Borsotto M, Widmann C, Brau F, et al. (2010) Neuroprotective and neuroproliferative activities of NeuroAid (MLC601, MLC901), a Chinese medicine, in vitro and in vivo. Neuropharmacology 58: 987-1001.
22. Hamill OP, Marty A, Neher E, Sakmann B, Sigworth FJ, (1981) Improved patch-clamp techniques for high-resolution current recording from cells and cell-free membrane patches. Pflugers Arch 391: 85-100.
23. Goldberg MP, Choi DW, (1993) Combined oxygen and glucose deprivation in cortical cell culture: calcium-dependent and calcium-independent mechanisms of neuronal injury. J Neurosci 13: 3510-3524.
24. Moha Ou Maati H, Borsotto M, Chatelain F, Widmann C, Lazdunski M, et al. (2012) Activation of ATP-sensitive potassium channels as an element of the neuroprotective effects of the Traditional Chinese Medicine MLC901 against oxygen glucose deprivation. Neuropharmacology 63: 692-700.
25. Leybaert L, De Ley G, de Hemptinne A, (1993) Effects of flunarizine on induced calcium transients as measured in fura-2-loaded neurons of the rat dorsal root ganglion. Naunyn Schmiedebergs Arch Pharmacol 348: 269-274.
26. Alexander GM, Carden WB, Mu J, Kurukulasuriya NC, McCool BA, et al. (2006) The native T-type calcium current in relay neurons of the primate thalamus. Neuroscience 141: 453-461.
27. Eckle VS, Digruccio MR, Uebele VN, Renger JJ, Todorovic SM, (2012) Inhibition of T-type calcium current in rat thalamocortical neurons by isoflurane. Neuropharmacology 63: 266-273.
28. Ichida S, Abe J, Komoike K, Imanishi T, Wada T, et al. (2005) Characteristics of omega-conotoxin GVI A and mVIIC binding to Cav 2.1 and Cav 2.2 channels captured by anti-Ca2+ channel peptide antibodies. Neurochem Res 30: 457-466.
29. Bourinet E, Stotz SC, Spaetgens RL, Dayanithi G, Lemos J, et al. (2001) Interaction of SNX482 with domains III and IV inhibits activation gating of alpha(1E) (Ca(V)2.3) calcium channels. Biophys J 81: 79-88.
30. Schweitz H, Heurteaux C, Bois P, Moinier D, Romey G, et al. (1994) Calcicludine, a venom peptide of the Kunitz-type protease inhibitor family, is a potent blocker of high-threshold Ca2+ channels with a high affinity for L-type channels in cerebellar granule neurons. Proc Natl Acad Sci U S A 91: 878-882.
31. Charnet P, Ouadid H, Richard S, Nargeot J, (1987) Electrophysiological analysis of the action of nifedipine and nicardipine on myocardial fibers. Fundam Clin Pharmacol 1: 413-431.
32. Clark NC, Nagano N, Kuenzi FM, Jarolimek W, Huber I, et al. (2003) Neurological phenotype and synaptic function in mice lacking the CaV1.3 alpha subunit of neuronal L-type voltage-dependent Ca2+ channels. Neuroscience 120: 435-442.
33. Hell JW, Westenbroek RE, Warner C, Ahlijanian MK, Prystay W, et al. (1993) Identification and differential subcellular localization of the neuronal class C and class D L-type calcium channel alpha 1 subunits. J Cell Biol 123: 949-962.
34. Berthet C, Lei H, Gruetter R, Hirt L, (2011) Early predictive biomarkers for lesion after transient cerebral ischemia. Stroke 42: 799-805.
35. Calvert JW, Zhang JH, (2005) Pathophysiology of an hypoxic-ischemic insult during the perinatal period. Neurol Res 27: 246-260.
36. Montero M, Poulsen FR, Noraberg J, Kirkeby A, van Beek J, et al. (2007) Comparison of neuroprotective effects of erythropoietin (EPO) and carbamylerythropoietin (CEPO) against ischemia-like oxygen-glucose deprivation (OGD) and NMDA excitotoxicity in mouse hippocampal slice cultures. Exp Neurol 204: 106-117.
37. Scheibe F, Klein O, Klose J, Priller J, (2012) Mesenchymal stromal cells rescue cortical neurons from apoptotic cell death in an in vitro model of cerebral ischemia. Cell Mol Neurobiol 32: 567-576.
38. Tauskela JS, Brunette E, O'Reilly N, Mealing G, Comas T, et al. (2005) An alternative Ca2+-dependent mechanism of neuroprotection by the metalloporphyrin class of superoxide dismutase mimetics. FASEB J 19: 1734-1736.
39. Quintard H, Borsotto M, Veyssiere J, Gandin C, Labbal F, et al. (2011) MLC901, a traditional Chinese medicine protects the brain against global ischemia. Neuropharmacology 61: 622-631.
40. Xiong ZG, Zhu XM, Chu XP, Minami M, Hey J, et al. (2004) Neuroprotection in ischemia: blocking calcium-permeable acid-sensing ion channels. Cell 118: 687-698.
41. de Souza AH, Castro CJ Jr., Rigo FK, de Oliveira SM, Gomez RS, et al. (2012) An Evaluation of the Antinociceptive Effects of Phalpha1beta, a Neurotoxin from the Spider Phoneutria nigriventer, and omega-Conotoxin mVIIA, a Cone Snail Conus magus Toxin, in Rat Model of Inflammatory and Neuropathic Pain. Cell Mol Neurobiol.
42. Diochot S, Baron A, Salinas M, Douguet D, Scarzello S, et al. (2012) Black mamba venom peptides target acid-sensing ion channels to abolish pain. Nature.
43. Mazzuca M, Heurteaux C, Alloui A, Diochot S, Baron A, et al. (2007) A tarantula peptide against pain via ASIC1a channels and opioid mechanisms. Nat Neurosci 10: 943-945.
44. Cognard C, Romey G, Galizzi JP, Fosset M, Lazdunski M, (1986) Dihydropyridine-sensitive Ca2+ channels in mammalian skeletal muscle cells in culture: electrophysiological properties and interactions with Ca2+ channel activator (Bay K8644) and inhibitor (PN 200-110). Proc Natl Acad Sci U S A 83: 1518-1522.